|
|
||||||||
School of Biomedical Sciences, University Medical School, Queen's Medical Center, Nottingham NG7 2UH; and Cardiovascular and Musculoskeletal Research Department, Zeneca Pharmaceuticals, Macclesfield SK10 4TG, United Kingdom
| |
ABSTRACT |
|---|
|
|
|---|
Pyruvate
dehydrogenase complex (PDC) activation status has been described as
being central in the regulation of tissue substrate oxidation as
outlined by the glucose fatty-acid cycle. In the present study we
examined the effects of reduced lipolysis, with use of nicotinate, and
increased PDC activation, with use of dichloroacetate (DCA), on
substrate utilization during 20 min of submaximal steady-state contraction (~80% of maximal O2
uptake) in canine gracilis skeletal muscle. At rest, PDC activation was
unchanged by nicotinate but was ~2.5-fold higher in the DCA group
than in the control group (P < 0.05). During contraction, PDC activation status increased to 3.5 mmol
acetyl-CoA · min
1 · kg
1
at 37°C in the control group, remained at 4.5 mmol
acetyl-CoA · min
1 · kg
1
at 37°C in the DCA group, but only increased to 2.2 mmol
acetyl-CoA · min
1 · kg
1
at 37°C in the nicotinate group (P < 0.05). However, the estimated amount of carbohydrate oxidized
during the 20-min contraction was similar across groups and did not
follow the degree of PDC activation (81.2 ± 22.9, 95.9 ± 11.7, and 89.3 ± 18.9 mmol glucosyl units/kg dry muscle for
control, nicotinate, and DCA, respectively). Thus it would appear that,
during steady-state contraction, PDC activation status does not
determine the rate of carbohydrate oxidation in skeletal muscle.
pyruvate dehydrogenase complex; glucose-fatty acid cycle; lipid; glycogen; acetylcarnitine
| |
INTRODUCTION |
|---|
|
|
|---|
THE REGULATION OF SUBSTRATE oxidation in contracting skeletal muscle has been the subject of intense investigation (2, 3, 11-13, 23). The glucose-fatty acid cycle (GFC) describes a mechanism for the regulation and integration of carbohydrate and lipid oxidation (24-26). According to the GFC, when the availability of nonesterified fatty acids (NEFA) increases, there is a concomitant reduction in carbohydrate oxidation (24-26). This is proposed to be a direct consequence of a reduction in the amount of pyruvate dehydrogenase complex (PDC) existing in its active, dephosphorylated form (PDCa) and is mediated by increases in the mitochondrial acetyl-CoA-to-CoASH ([acetyl-CoA]/[CoASH]) and NADH-to-NAD+ concentration ratios (24-26). In resting skeletal muscle the mechanisms underlying the regulation of substrate oxidation appear to be consistent with the operation of the GFC (16, 22, 24, 33). Indeed, recent work has demonstrated a reduction in PDCa when the [acetyl-CoA]/[CoASH] ratio is increased by acetate infusion (22). The effect of reduced plasma NEFA availability on resting skeletal muscle PDC status has not been examined in healthy volunteers. However, it has been demonstrated that inhibition of lipolysis failed to alter PDCa during euglycemic conditions in resting skeletal muscle from patients with non-insulin-dependent diabetes mellitus (33).
When lipid availability has been increased during exercise, a reduction in muscle glycogen utilization or muscle carbohydrate oxidation has often (10, 22), although not always (13, 27), been observed. Furthermore, when lipid availability has been reduced by using nicotinate, a more rapid rate of muscle glycogen utilization and whole body carbohydrate oxidation has been observed during prolonged exercise (3, 5, 12). Importantly, it appears that nicotinate inhibits intramuscular and adipose lipolysis (12). In all these cases (3, 5, 12, 18, 19) the regulatory mechanism attributed to mediating the increase in carbohydrate oxidation has been the GFC. However, PDCa has never been assessed under conditions of reduced lipid availability, such that the operation of the GFC in contracting skeletal muscle has not been established and the regulatory mechanisms controlling substrate oxidation during exercise remain unclear (10, 22, 23). In particular, those studies that have demonstrated a glycogen-sparing effect of lipid infusion and simultaneously assessed PDCa and the [acetyl-CoA]/[CoASH] ratio have failed to establish PDC as the regulatory mechanism for their observations (10, 22). When PDC has been activated using dichloroacetate (DCA), blood lactate concentration was reduced during submaximal exercise (6); however, the effect of this reduction on muscle carbohydrate oxidation has not been established.
It was our aim, therefore, to examine the role of lipid availability and PDC activation status on carbohydrate utilization during moderately intense submaximal skeletal muscle contraction. This intensity reflects the most common workload utilized where the GFC has been interpreted to operate (12, 18, 19). This was achieved by using nicotinate, which inhibits hormone-sensitive lipase-mediated lipolysis and hence NEFA availability to the contracting muscle (5, 12, 15). Hormone-sensitive lipase is the main mediator of lipolysis in adipose and skeletal muscle tissue (34). In addition, PDC was activated using sodium DCA at a dose that maximally activates the enzyme complex (29). We hypothesized that if PDC was directly responsible for regulating steady-state carbohydrate oxidation, then this would be most evident when the enzyme complex was maximally activated.
| |
METHODS |
|---|
|
|
|---|
Animals. Eighteen female beagle dogs (Zeneca Pharmaceuticals, Alderley Park, Cheshire, UK) weighing 13.9 ± 1.1 kg and aged 12.2 ± 0.9 mo were divided into three groups: saline control (n = 6), nicotinate (n = 6), and DCA (n = 6).
Surgical procedures.
After an overnight fast, each animal was premedicated with morphine
sulfate (10 mg im). After 30 min, anesthesia was induced with
pentobarbitone sodium (45 mg/kg body mass iv; Sagatal, Rhône Merieux, Harlow, UK) and maintained by intravenous infusion (0.11 ± 0.00 mg · kg
1 · min
1).
The animals were then artificially ventilated, and surgical procedures
were carried out as described previously (32). Briefly, the right
brachial artery was cannulated for recording of systemic blood
pressure, and the left brachial artery and vein were cannulated for
collection of arterial blood samples and infusion of saline, nicotinate, or DCA. The gracilis was vascularly isolated, with only the
supply from the brachial artery and to the femoral vein left intact.
Blood flow was measured using an electromagnetic flow probe (10-mm
circumference; Carolina Medical Electronics, King, NC) placed around
the femoral artery. In situ calibration of the flow probe was completed
at the end of the experiment with use of the dog's own blood (timed
collection), and zero flow was determined by occluding blood flow
distal to the flow probe at intervals during the experiment. The
popliteal artery was catheterized for recording gracilis muscle
perfusion pressure. Heparin was infused (Multiparin, 1 U · kg
1 · min
1
iv) for the duration of the experiment. The distal tendon of the muscle
was attached to an isometric force transducer (model FTC 10, Grass,
Quincy, Medfield, MA). The animals were then infused with saline (45 ml), nicotinate (45 mg/kg), or DCA (300 mg/kg) over a period of 45 min.
Muscle stimulation parameters.
The resting length of the muscle was altered to obtain a standard
resting tension of 300 g. At 60 min after the onset of infusion, muscle
contraction was induced via electrical stimulation of the obturator
nerve (model S88 stimulator, Grass). Square-wave impulses of 0.1-ms
duration, 3-Hz frequency, and 10-V intensity were applied for 20 min,
which results in a steady-state maximal oxygen consumption (
O2 max) of ~80%.
It was determined in a pilot study that a stimulus intensity of 10 V
resulted in maximal twitch force production, indicating that complete
muscle fiber recruitment was achieved.
Blood collection and analysis. Arterial and venous blood samples, obtained at rest and during the stimulation protocol (between minutes 10-12 and 18-20), were taken from the brachial artery and femoral vein and used for blood pH, PCO2, and PO2 determination (model 280 blood-gas system, Ciba-Corning, Medfield, MA). Hemoglobin and total oxygen saturation were also assessed using a CO-oximeter (model 482, Instrumentation Laboratory, Lexington, MA). Further blood samples (1 ml) were collected in tubes containing 3.2% trisodium citrate, and after centrifugation, plasma was used for analysis of lactate, NEFA, and glucose. Plasma samples for glucose analysis were kept on ice, and glucose was measured spectrophotometrically at the end of each experiment (Glucose Autostat GA1120, Clandon, Aldershot, UK). Plasma samples for lactate (lactate reagent kit, Sigma Chemical, Poole, UK) and NEFA (NEFA C kit, Wako Chemicals, Neuss, Germany) were frozen for later spectrophotometric analysis. For the saline and nicotinate groups the blockage of a venous catheter resulted in arteriovenous differences being available only from five of the six experiments in each case. When this happened an average value for glucose uptake and lactate efflux, calculated from the respective groups, was used to calculate total carbohydrate oxidation rates.
Muscle collection and analysis. A resting muscle biopsy was obtained at the end of the infusion period by use of the needle biopsy technique of Bergström and Hultman (2). After 20 min of stimulation, the muscle was freeze-clamped during contraction and a thin piece of muscle was excised, divided into two portions, and stored under liquid nitrogen. Subsequently, one portion was freeze-dried, dissected free from visible connective tissue and blood, powdered, and extracted in 0.5 M perchloric acid containing 1 mM EDTA. After centrifugation, the supernatant was neutralized with 2.2 M KHCO3 and used for spectrophotometric determination of ATP, phosphocreatine, creatine, and lactate (14). The supernatant was also used for the determination of free carnitine and acetylcarnitine by enzymatic assays with use of radioisotopic substrates, as described previously (7). Freeze-dried muscle powder was used for the determination of muscle glycogen (14). In the remaining portion of frozen muscle, PDC activation was assessed as described previously (9).
Calculations and statistics. Muscle carbohydrate utilization was calculated from changes in muscle glycogen concentration from rest and muscle glucose uptake during contraction (values obtained during the last 10 min of contraction). Muscle lactate accumulation and muscle lactate production (calculated from arteriovenous differences and converted to mmol/kg dry muscle) were summed and, after conversion to glucosyl units (divided by a factor of 2), were subtracted from muscle carbohydrate utilization to provide an estimate of muscle carbohydrate oxidation during the 20-min contraction period (10, 32). Muscle carbohydrate oxidation can then be expressed as a rate per minute by dividing by 20. The estimate of carbohydrate oxidation was also converted to millimoles of acetyl-CoA per kilogram of wet muscle to give the calculated flux through PDC for direct comparison with the measurements of PDC. This was done by converting the rate of carbohydrate oxidation to wet muscle mass (by dividing by 4.3) and converting to acetyl-CoA (by dividing by a factor of 2). Changes in muscle acetylcarnitine during contraction were not taken into account in this calculation, because it is unclear what proportion of the acetyl groups was derived from carbohydrate. However, even if it were assumed that all acetylcarnitine was derived from carbohydrate, the changes during contraction did not significantly alter the calculated flux through PDC (calculation not shown).
Values are means ± SE. Comparisons between treatments were made using ANOVA. When a significant F value was found (P < 0.05), Tukey's post hoc test was used to locate the differences, and significance was accepted at the 5% level.| |
RESULTS |
|---|
|
|
|---|
Contractile function. There was no significant difference in peak isometric tension between any of the groups (4,437 ± 259, 4,189 ± 212, and 3,662 ± 445 g/100 g tissue for control, nicotinate, and DCA, respectively). Isometric tension declined ~12% during the initial few minutes of contraction and thereafter remained relatively constant for the remainder of the stimulation period. No significant differences in isometric tension existed between any of the groups at the end of the 20-min contraction period (3,842 ± 317, 3,632 ± 250, and 3,335 ± 186 g/100 g tissue for control, nicotinate, and DCA, respectively).
Hemodynamics and plasma metabolites. There was no effect of nicotinate or DCA on muscle blood flow or perfusion pressure during contraction compared with the control group (Table 1). Nicotinate resulted in a reduction in resting arterial NEFA concentration from 0.29 ± 0.05 to 0.09 ± 0.02 mmol/l (P < 0.05). This was lower than the NEFA concentration measured in the control group (0.23 ± 0.03 mmol/l, P < 0.05). Plasma NEFA concentration was also reduced by DCA from 0.24 ± 0.02 to 0.12 ± 0.01 mmol/l. Arterial NEFA concentration did not change further during the stimulation protocol in any of the groups. NEFA uptake was fourfold lower after nicotinate and threefold lower after DCA than in the control group during the 20-min contraction period (Table 1). Arterial lactate concentration was significantly reduced by DCA (0.4 ± 0.1 mmol/l, P < 0.05) but did not differ between control and nicotinate groups (1.60 ± 0.19 and 1.48 ± 0.26 mmol/l for control and nicotinate, respectively). There were no significant differences among the three groups in muscle lactate efflux or muscle glucose uptake (Table 1).
|
Muscle metabolites.
Muscle ATP and phosphocreatine concentrations did not significantly
differ between groups at rest or during contraction (Table 2). Nicotinate and DCA reduced resting
muscle lactate concentration compared with the control group (Table 2).
During contraction, DCA reduced lactate accumulation compared with the
control and nicotinate groups. Resting muscle glycogen concentration
was similar across groups, and utilization during contraction did not
differ between groups (Table 2). Carbohydrate oxidation, calculated from glycogen utilization, glucose uptake, and muscle lactate production (see METHODS), did not
differ between groups over the 20-min stimulation period (Fig.
1). Nicotinate did not significantly affect PDCa at
rest, whereas PDCa was ~2.5-fold higher in the DCA group (1.9 ± 0.2, 1.7 ± 0.2, and 4.5 ± 0.4 mmol
acetyl-CoA · min
1 · kg
wet wt
1 at 37°C for
control, nicotinate, and DCA, respectively). During contraction, PDCa
was significantly lower in the nicotinate group than in the control and
DCA groups (Fig. 2;
P < 0.05). There was no
effect of nicotinate on muscle acetylcarnitine concentration at rest or
during contraction; however, DCA increased acetylcarnitine concentration at rest by ~10-fold (Table 2). During contraction the
acetylcarnitine concentration fell in the DCA group, such that there
was no difference in acetylcarnitine concentration between groups
(Table 2). Free carnitine concentration was significantly lower in the
DCA group at rest than in the control and nicotinate groups, but no
differences were observed between groups during contraction (Table 2).
The sum of the acid-soluble carnitine esters (acetylcarnitine + free
carnitine) did not differ at rest or during contraction between groups
(Table 2).
|
|
|
| |
DISCUSSION |
|---|
|
|
|---|
In accordance with the GFC (24-26), activating PDC, by using DCA, would be expected to result in an increase in carbohydrate oxidation during steady-state skeletal muscle contraction. Similarly, a decrease in lipid availability during contraction would be expected to be accompanied by an increase in carbohydrate oxidation mediated through an increase in PDCa. However, when PDC was converted to its active form before the onset of contraction, no alteration in the rate of carbohydrate oxidation during steady-state contraction was observed. Furthermore, we observed that PDCa was reduced during steady-state contraction when lipolysis was inhibited, yet the rate of carbohydrate oxidation was maintained. Because PDCa varied greatly among the three groups but carbohydrate oxidation remained identical, it can be concluded that the GFC does not operate in skeletal muscle during submaximal steady-state contraction.
In resting muscle, PDC is thought to be responsible for the regulation of pyruvate decarboxylation and hence carbohydrate oxidation (24). The PDC exists in a dephosphorylated (active) form and a phosphorylated (inactive) form. The interconversion between the active and the inactive form of PDC is regulated by a phosphatase-kinase system, which is, in turn, subject to control by the end products of the PDC-catalyzed reaction, i.e., acetyl-CoA and NADH (1). During contraction, however, physiological activation of PDC is thought to be partly achieved through an increase in the intramitochondrial calcium concentration (1), although the in vivo importance of calcium in PDC activation has not been determined. It has also been suggested that other metabolites, such as pyruvate and ADP, have a regulatory influence on the degree of PDC activation during steady-state contraction (8, 10, 22).
DCA has been used to decrease lactate production at rest and during
submaximal contraction, presumably by increasing PDC activation and
theoretically flux through the PDC reaction (6, 17, 31). In addition,
reducing the amount of acetyl-CoA derived from
-oxidation normally increases muscle glycogen oxidation during exercise (3, 19). This increase in glycogen oxidation has been explained by a
decrease in the [acetyl-CoA]/[CoASH] ratio
resulting from a reduction in lipid availability and, therefore,
greater PDC activation (18). The importance of the
[acetyl-CoA]/[CoASH] ratio as a regulator of
PDC or carbohydrate oxidation during steady-state contraction has not,
however, withstood investigation (8, 22).
During contraction the ratio of acetylcarnitine to free carnitine concentration reflects changes in the [acetyl-CoA]/[CoASH] ratio (7, 19). It would be expected that a high [acetyl-CoA]/[CoASH] ratio, represented in the current study by a high acetylcarnitine concentration, would result in the inhibition of PDC activation. However, it is clear from the current study that PDC can range from ~40 to ~100% activated during contraction with apparently similar [acetyl-CoA]/[CoASH] ratios. The [acetyl-CoA]/[CoASH] ratios are apparently similar, since in the present study acetylcarnitine concentration did not significantly differ between groups. Putman et al. (22, 23) also demonstrated that PDC activation was dissociated from changes in the [acetyl-CoA]/[CoASH] ratio during exercise. At rest the [acetyl-CoA]/[CoASH] ratio was altered by an infusion of acetate and PDCa was reduced, but these effects on the [acetyl-CoA]/[CoASH] ratio or PDCa did not persist during contraction (22). However, in these studies and in the present study, muscle biopsies were taken during steady-state contraction. It is possible that the [acetyl-CoA]/[CoASH] ratio may influence the rate of activation of PDC and hence influence carbohydrate utilization (21) and lactate production (30) during the initial period of contraction. Indeed, consistent with our previous data, DCA reduced the muscle "oxygen deficit" by ~40% (30, 31). It should be indicated that this reflects overall substrate delivery during the intial, non-steady-state situation and is not a relevant factor in consideration of the control of steady-state carbohydrate oxidation, as addressed by the GFC theory (24).
We found that when lipolysis was inhibited, so reducing the competition
between acetyl-CoA derived from the PDC reaction and that derived from
-oxidation, activation of PDC was reduced. This is contrary to what
would be expected if the GFC operated in contracting skeletal muscle
(24-26). Despite this reduction in the enzyme activation status,
flux through the PDC reaction was maintained during contraction; i.e.,
the rate of muscle carbohydrate oxidation did not differ between the
control and nicotinate groups. Activation of PDC requires covalent
modification of the enzyme complex, such that an accurate assessment of
its degree of activation in vivo is achieved by in vitro assessment
(1). Flux through PDC during contraction can be estimated from the
amount of carbohydrate oxidized, and the calculated flux in all three
groups was ~2.0 mmol
acetyl-CoA · min
1 · kg
wet wt
1. This estimated
flux, however, is similar to the degree of activation of PDC in the
nicotinate group only (Fig. 1). Indeed, the calculated flux in the
control group represented only ~60% of the measured PDC activation,
whereas the corresponding values in the nicotinate and DCA groups were
~90% and ~40% of the measured PDC activation, respectively.
In the present study we did not significantly increase muscle
carbohydrate oxidation with nicotinate (numerically it was ~18% higher). This may be a reflection of the limited contribution of lipid
oxidation under present stimulation intensity (~20%). However,
failure to observe the operation of the GFC is not restricted to the
higher workloads [e.g., Ravussin et al. (27) utilized a workload
of ~40%
O2 max].
Importantly, in the present study the activation of PDC during
contraction was in excess of the required steady-state catalytic
activity and appeared to be unrelated to the rate of carbohydrate
oxidation during steady-state contraction.
From the above data it appears that PDC is not responsible for the
regulation of carbohydrate oxidation during skeletal muscle contraction. It is important, however, at this point to discuss what
factors may have been responsible for the changes in PDC activation
status in the present series of experiments. First, the reduction in
PDCa in the nicotinate group during contraction suggests that PDC
activation may be, under control conditions, elevated when acetyl
groups are also derived from
-oxidation. This could be explained if,
as suggested by others (10, 22, 23), pyruvate accumulation is an
important regulator of PDCa during contraction. It is suggested,
therefore, that as acetyl group availability increases, pyruvate
accumulation within the mitochondria also increases, and so greater
inhibition of pyruvate dehydrogenase kinase occurs, resulting in less
inhibition to activation of PDC. This would be consistent with
observations that complete PDC activation occurs at a workload of 75%
O2 max, i.e., when pyruvate availability would be expected to exceed the rate of pyruvate
oxidation and lactate would be continually formed (8, 10). Because
pyruvate enters the mitochondria via a highly efficient monocarboxylate
transport system, which has a maximal transport capacity that exceeds
the catalytic activity of PDC by severalfold (4), then pyruvate uptake
by the mitochondria is unrelated to the demand for oxidative substrate
but rather reflects the inherent characteristic of the pyruvate
transporter and the rate of glycolysis.
It is suggested that by inhibiting lipid availability in the current study we reduced the degree of intramitochondrial pyruvate accumulation, hence relieving the inhibition on pyruvate dehydrogenase kinase, leading to phosphorylation and inactivation of PDC. In studies in which PDC activation was examined during submaximal exercise with elevated lipid availability (10, 22), however, no increase in the amount of PDCa was observed. However, in these studies, PDC activation was essentially maximal in the control condition, such that any potentiation of PDC activation, through greater mitochondrial pyruvate accumulation, was unlikely to be observed (10, 22). In conclusion, despite the 50% range in the extent of PDC activation status, carbohydrate oxidation was similar across the three groups. It would appear, therefore, that, contrary to the operation of the GFC, the extent of PDC activation is not a major physiological regulator of carbohydrate oxidation during steady-state skeletal muscle contraction.
Perspectives
The role of the GFC, as proposed by Randle and co-workers in the early 1960s (25), has directed our understanding of the way in which oxidation of carbohydrate and lipid is regulated within skeletal muscle tissue. A key feature of the GFC is that glucose oxidation is inhibited by NEFA oxidation through an acetyl-CoA- and NADH-mediated inhibition of the PDC and an increase in cytosolic citrate concentration, which inhibits phosphofructokinase activity and hence glycolytic flux. In vitro evidence in support of these possibilities has been presented (1, 24-26), although the physiological significance of the concentration of citrate used in vitro to inhibit phosphofructokinase has been questioned (20).Overall it appears that the GFC may operate in vivo in noncontracting skeletal muscle (16, 22, 24, 33). It is apparent, however, that during contraction the GFC does not operate in skeletal muscle (10, 22). Indeed, it has been demonstrated in the present study that the activation status of PDC can vary about twofold without influencing steady-state carbohydrate oxidation. We must consider alternative mechanisms for the integration of carbohydrate and lipid oxidation in contracting skeletal muscle, e.g., the role of carnitine availability in determining fatty acid transport across the mitochondrial membrane during steady-state contraction. We previously pointed out, as have others, that carnitine availability may be important in regulating carbohydrate metabolism early during exercise (8). However, the extent of the reduction in free carnitine concentration (or the increase in acetylcarnitine) during the first few minutes of submaximal contraction is a function of exercise intensity (8) and may thereafter be a determinant of the rate of carnitine-mediated transport of long-chain acyl groups across the mitochondrial membrane via carnitine palmitoyl-transferase I. This would provide a simple link between exercise intensity and the reduction in lipid oxidation rates observed at high work rates (28).
| |
ACKNOWLEDGEMENTS |
|---|
J. A. Timmons is supported by the Defence Evaluation Research Agency, Centre for Human Sciences.
| |
FOOTNOTES |
|---|
Address for reprint requests: J. A. Timmons, Discovery Biology, Central Research, Pfizer Limited, Sandwich, Kent CT13 9NJ, UK (E-mail: James_Timmons{at}sandwich.pfizer.com).
Received 3 September 1997; accepted in final form 7 January 1998.
| |
REFERENCES |
|---|
|
|
|---|
1.
Ashour, B.,
and
R. G. Hansford.
Effect of fatty acids and ketones on the activity of pyruvate dehydrogenase in skeletal muscle mitochondria.
Biochem. J.
214:
725-736,
1983[Medline].
2.
Bergström, J.,
and
E. Hultman.
A study of the glycogen metabolism during exercise in man.
Scand. J. Clin. Lab. Invest.
19:
218-228,
1967[Medline].
3.
Bergström, J.,
E. Hultman,
L. Jorfeldt,
B. Pernow,
and
J. Wahren.
Effect of nicotinic acid on physical working capacity and on metabolism of muscle glycogen in man.
J. Appl. Physiol.
26:
170-176,
1969
4.
Bünger, R.,
and
R. T. Mallet.
Mitochondrial pyruvate transport in working guinea-pig heart. Work-related vs. carrier-mediated control of pyruvate oxidation.
Biochim. Biophys. Acta
1151:
223-236,
1993[Medline].
5.
Carlson, L. A.,
R. J. Havel,
L.-G Ekelund,
and
A. Holmgren.
Effect of nicotinic acid on the turnover rate and oxidation of the free fatty acids of plasma in man during exercise.
Metabolism
12:
837-845,
1963.
6.
Carraro, F.,
S. Klein,
J. I. Rosenblatt,
and
R. R. Wolfe.
Effect of dichloroacetate on lactate concentration in exercising humans.
J. Appl. Physiol.
66:
591-597,
1989
7.
Cederblad, G.,
J. I. Carlin,
D. Constantin-Teodosiu,
P. Harper,
and
E. Hultman.
Radioiostopic assays of CoASH and carnitine and their acetylated forms in human skeletal muscle.
Anal. Biochem.
185:
274-278,
1990[Medline].
8.
Constantin-Teodosiu, D.,
J. I. Carlin,
G. Cederblad,
R. C. Harris,
and
E. Hultman.
Acetyl group accumulation and pyruvate dehydrogenase activity in human skeletal muscle during incremental exercise.
Acta Physiol. Scand.
143:
367-372,
1991[Medline].
9.
Constantin-Teodosiu, D.,
G. Cederblad,
and
E. Hultman.
A sensitive radioisotopic assay of pyruvate dehydrogenase complex in human muscle tissue.
Anal. Biochem.
198:
347-351,
1991[Medline].
10.
Dyck, D. J.,
C. T. Putman,
G. J. F. Heigenhauser,
E. Hultman,
and
L. L. Spriet.
Regulation of fat-carbohydrate interaction in skeletal muscle during intense aerobic cycling.
Am. J. Physiol.
265 (Endocrinol. Metab. 28):
E852-E859,
1993
11.
Gollnick, P. D.
Metabolism of substrates: energy substrate metabolism during exercise and as modified by training.
Federation Proc.
44:
353-357,
1985[Medline].
12.
Gollnick, P. D.,
B. Pernow,
B. Essen,
E. Jansson,
and
B. Saltin.
Availability of glycogen and plasma NEFA for substrate utilisation in leg muscle of man during exercise.
Clin. Physiol.
1:
27-42,
1981.
13.
Hargreaves, M.,
B. Kiens,
and
E. A. Richter.
Effect of increased plasma free fatty acid concentrations on muscle metabolism in exercising men.
J. Appl. Physiol.
70:
194-200,
1991
14.
Harris, R. C.,
E. Hultman,
and
L.-O. Nordesjö.
Glycogen, glycolytic intermediates and high energy phosphates determined in biopsy samples of musculus femoris of man at rest. Methods and variance values.
Scand. J. Clin. Lab. Invest.
33:
109-120,
1974[Medline].
15.
Holm, C.,
P. Belfrage,
and
G. Fredrikson.
Immunological evidence for the presence of hormone-sensitive lipase in rat tissues other than adipose tissue.
Biochem. Biophys. Res. Commun.
148:
99-105,
1987[Medline].
16.
Kelly, D. E.,
M. Mookan,
J.-A. Simoneau,
and
L. J. Mandarino.
Interaction between glucose and free fatty acid metabolism in human skeletal muscle.
J. Clin. Invest.
92:
91-98,
1993.
17.
McVeigh, J.,
and
G. D. Lopaschuk.
Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts.
Am. J. Physiol.
259 (Heart Circ. Physiol. 28):
H1079-H1085,
1990
18.
Murray, R.,
W. P. Bartoli,
D. E. Eddy,
and
M. K. Horn.
Physiological and performance responses to nicotinate-acid ingestion during exercise.
Med. Sci. Sports Exerc.
27:
1057-1062,
1995[Medline].
19.
Pernow, B.,
and
B. Saltin.
Availability of substrates and capacity for prolonged exercise in man.
J. Appl. Physiol.
31:
416-422,
1971
20.
Peters, S. J.,
and
L. L. Spriet.
Skeletal muscle phosphofructokinase activity examined under physiological conditions in vitro.
J. Appl. Physiol.
78:
1853-1858,
1995
21.
Putman, C. T.,
N. L. Jones,
L. C. Lands,
T. M. Bragg,
M. G. Hollidge-Horvat,
and
G. J. F. Heigenhauser.
Skeletal muscle pyruvate dehydrogenase activity during maximal exercise in humans.
Am. J. Physiol.
269 (Endocrinol. Metab. 32):
E458-E468,
1995
22.
Putman, C. T.,
L. L. Spriet,
E. Hultman,
D. J. Dyck,
and
G. J. F. Heigenhauser.
Skeletal muscle pyruvate dehydrogenase activity during acetate infusion in humans.
Am. J. Physiol.
268 (Endocrinol. Metab. 31):
E1007-E1017,
1995
23.
Putman, C. T.,
L. L. Spriet,
E. Hultman,
M. I. Lindinger,
L. C. Lands,
R. S McKelvie,
G. Cederblad,
N. L. Jones,
and
G. J. F. Heigenhauser.
Pyruvate dehydrogenase activity and acetyl group accumulation during exercise after different diets.
Am. J. Physiol.
265 (Endocrinol. Metab. 28):
E752-E760,
1993
24.
Randle, P. J.
Fuel selection in animals.
Biochem. Soc. Trans.
14:
799-806,
1986[Medline].
25.
Randle, P. J.,
P. B. Garland,
C. N. Hales,
and
E. A. Newsholme.
The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus.
Lancet
1:
785-789,
1963[Medline].
26.
Randle, P. J.,
D. A. Priestman,
S. C. Mistry,
and
A. Halsall.
Glucose fatty acid interactions and the regulation of glucose disposal.
J. Cell. Biochem.
55S:
1-11,
1994.
27.
Ravussin, E.,
C. Borgardus,
K. Scheidegger,
B. Lagrange,
E. D. Horton,
and
E. S. Horton.
Effect of elevated NEFA on carbohydrate and lipid oxidation during prolonged exercise in humans.
J. Appl. Physiol.
60:
893-900,
1986
28.
Romijn, J. A.,
E. F. Coyle,
L. S. Sidossis,
A. Gastadelli,
J. F. Horowitz,
E. Enert,
and
R. R. Wolfe.
Regulation of endogenous fat and carbohydrate metabolism in relation to exercise intensity and duration.
Am. J. Physiol.
265 (Endocrinol. Metab. 28):
E380-E391,
1993
29.
Stacpoole, P. W.
The pharmacology of dichloroacetate.
Metabolism
38:
1124-1144,
1989[Medline].
30.
Timmons, J. A.,
S. M. Poucher,
D. Constantin-Teodosiu,
I. A. Macdonald,
and
P. L. Greenhaff.
The metabolic responses from rest to steady state determine contractile function in ischemic canine skeletal muscle.
Am. J. Physiol.
273 (Endocrinol. Metab. 36):
E233-E238,
1997
31.
Timmons, J. A.,
S. M. Poucher,
D. Constantin-Teodosiu,
V. Worrall,
I. A. Macdonald,
and
P. L. Greenhaff.
Increased acetyl group availability enhances contractile function of canine skeletal muscle during ischemia.
J. Clin. Invest.
97:
879-883,
1996[Medline].
32.
Timmons, J. A.,
S. M. Poucher,
D. Constantin-Teodosiu,
V. Worrall,
I. A. Macdonald,
and
P. L. Greenhaff.
The metabolic responses of canine gracilis muscle during contraction with partial ischemia.
Am. J. Physiol.
270 (Endocrinol. Metab. 33):
E400-E406,
1996
33.
Vaag, A.,
P. Skött,
P. Damsbo,
M. Gall,
E. A. Richter,
and
H. Beck-Nielsen.
Effect of the antilipolytic nicotinic acid analogue acipimox on whole body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
J. Clin. Invest.
88:
1282-1290,
1991.
34.
Van Der Vusse, G. J.,
and
R. S. Reneman.
Lipid metabolism in muscle.
In: Handbook of Physiology. Exercise: Regulation and Integration of Multiple Systems. Bethesda, MD: Am. Physiol. Soc., 1996, sect. 12, chapt. 21, p. 952-994.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |